13.71
-0.05(-0.36%)
Currency In USD
| Previous Close | 13.76 |
| Open | 13.89 |
| Day High | 13.99 |
| Day Low | 13.59 |
| 52-Week High | 72.37 |
| 52-Week Low | 9.12 |
| Volume | 284,770 |
| Average Volume | 968,379 |
| Market Cap | 556.84M |
| PE | -80.65 |
| EPS | -0.17 |
| Moving Average 50 Days | 14.02 |
| Moving Average 200 Days | 29.03 |
| Change | -0.05 |
If you invested $1000 in Keros Therapeutics, Inc. (KROS) since IPO date, it would be worth $682.77 as of June 25, 2025 at a share price of $13.71. Whereas If you bought $1000 worth of Keros Therapeutics, Inc. (KROS) shares 3 years ago, it would be worth $500.91 as of June 25, 2025 at a share price of $13.71.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Keros Announces Return of $375 Million in Excess Capital to Stockholders
GlobeNewswire Inc.
Jun 09, 2025 10:55 AM GMT
Concludes Strategic Alternatives Review and Provides Update on Development of KER-065LEXINGTON, Mass., June 09, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company
Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference
GlobeNewswire Inc.
Jun 06, 2025 8:01 PM GMT
LEXINGTON, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with di
Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring
GlobeNewswire Inc.
May 29, 2025 10:55 AM GMT
Discontinues Development of Cibotercept in PAH Announces Corporate Restructuring to Align Operations with Ongoing Strategic Priorities LEXINGTON, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”, the “Company” or “we”) (Nas